InMode Ltd.

NEW YORK--(BUSINESS WIRE)--Steel Partners Holdings L.P. (together with its affiliates, “Steel”), a significant, long-standing shareholder of InMode Ltd. (“InMode” or the “Company”) (Nasdaq: INMD), today issued an open letter to all InMode stakeholders. The full text of the letter is below. October 19, 2026 To All InMode Stakeholders: Steel Partners Holdings L.P. (together with its affiliates, “Steel”) is a significant, long-standing shareholder of InMode Ltd. On July 9, 2026, we proposed to acq.

YOKNEAM, Israel, Oct. 13, 2026 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical technologies, announced today that it expects to release its financial results for the third quarter of 2026 before the Nasdaq market opens on Wednesday, November 11, 2026.

PAVmed (NASDAQ: PAVM - Get Free Report) and InMode (NASDAQ: INMD - Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, institutional ownership, analyst recommendations, dividends, profitability, risk and earnings. Valuation and Earnings This table compares PAVmed and InMode"s

InMode remains rangebound as US platform sales decline, but international growth and recurring consumables revenue provide stabilization. I maintain a 'buy' rating, downgraded from 'strong buy,' citing cyclical industry softness, macro headwinds, and management's capital allocation frustrations. INMD's robust net cash (~$497M), aggressive buybacks, and proprietary technology underpin a strong moat, yet sentiment is hampered by leadership doubts and execution risk.